Bluebird Bio Wins Gene Therapy Patent Dispute

In an opinion issued on May 16, 2025, a Delaware federal judge granted bluebird bio’s request for summary judgment of noninfringement in a patent dispute brought by San Rocco Therapeutics LLC. The ruling is a win for Morris Nichols client bluebird, protecting its multimillion-dollar blood-disorder treatments, Zynteglo and Lyfgenia. Jack Blumenfeld, Jeremy Tigan, Anthony Raucci, and co-counsel from Paul Hastings represented bluebird.